Dyne Therapeutics is a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases by addressing the root cause of disease through its FORCE™ platform. The platform uses an antigen-binding fragment (Fab) that leverages transferrin receptor 1 (TfR1) to enable broad distribution to muscle and the central nervous system (CNS). We have assembled an exceptional team of employees focused on fostering a differentiated culture and working toward delivering functional improvement for individuals, families and communities.
The following summarizes our key corporate responsibility initiatives:
Exceptional team fostering a differentiated culture
At Dyne we are committed to attracting, retaining, and developing our employees (Dynamos) through comprehensive initiatives centered on enhancing engagement in our business and culture. As of the end of 2025, we employed approximately 251 Dynamos.
We leverage a variety of networks, including our own Dynamos, to recruit potential candidates and promote equal opportunity in how we evaluate candidates for roles based on technical qualifications as well as fit within our organization. New employees benefit from a robust onboarding program that includes a comprehensive online platform accessible from the moment that a candidate accepts their offer to prepare new Dynamos for their first day and beyond. After the initial in-person orientation, Dynamos continue onboarding through modules covering Dyne’s platform, pipeline, benefits and culture. They also participate in scheduled one-on-one cross-functional meetings over the first few weeks of joining Dyne to ensure they 
feel welcomed and become familiar with colleagues and their areas of expertise. In addition, new employees work closely with their manager to plan and execute performance goals.
Beyond onboarding, professional development takes on many forms at Dyne. We encourage Dynamos to undertake stretch roles, projects, and assignments to learn as part of cross-functional teams. In 2025, we offered more than 14 different development sessions and a management development journey totaling over 200 hours of formal development opportunities. Targeted subject areas included: manager effectiveness, clear and impactful communication, accountability, giving and receiving feedback, effective presentation development and delivery, and time and meeting management. At Dyne, we prioritize regular feedback and hold quarterly check in conversations. We set aside time for these discussions for managers and employees to meet and discuss performance and career development. These weeks foster performance and development alignment through meaningful conversations between managers and their teams.
We also have a number of initiatives designed to ensure frequent communication and engagement with employees, including regular All-Hands company meetings, Dyne 411 or “Lunch ‘n Learn” sessions led by internal experts, monthly roundtable discussions with our executive committee or senior management and FORCEs in Biotech, which give Dynamos access to leaders across the field and deepen their understanding of the biotech landscape and Dyne’s role within it.
As part of our efforts to develop the next generation of leaders in life sciences, we offer internships and co-op positions across Dyne. In 2025, we hosted 11 interns and co-ops.
We recognize the importance of creating an environment that encourages diverse perspectives, backgrounds, and creative approaches to advancing therapeutics that provide functional improvement – it makes us stronger and better positioned to achieve our mission. We also unite in dedication to our core values, which are the foundation of our company culture. Informed by employee feedback and shaped through cross-functional collaboration, we refreshed our core values to support the company’s continued growth and future direction. Our Core Values reinforce alignment across the organization and guide how we work together to deliver meaningful impact.
Our Core Values
Learn more
Delivering for patients
One Dyne community
One mission, no ego
Embrace accountability & excellence
Fearless innovation
We have a cross-functional and multi-level Culture Team that is charged with identifying ways to reinforce our company values, bring insights from across the business, and drive initiatives, including team building, wellness, community and social events. In 2025, we conducted a toy donation drive and participated in walks to support the neuromuscular disease community, including the Jett Foundation’s National Challenge and the FSHD Society’s Walk & Roll to cure facioscapulohumeral muscular dystrophy (FSHD). We also held our fourth FORCE for Good Service Day, contributing more than 390 volunteer hours across seven Greater Boston nonprofits. Our team assembled 390 STEM kits to empower underrepresented youth, prepared 144 backpacks for K–12 students facing homelessness and built 248 outfit packs while sorting clothing for children experiencing clothing insecurity. We removed invasive water chestnut plants, filling over 225 baskets to help restore the local aquatic ecosystem, and packed 214 meal bags while prepping hundreds of pounds of food for people experiencing serious illness.
Dyne offers employees a competitive and comprehensive compensation and benefits package, which we believe is an important part of supporting the health and well-being of our employees and their families. These include:
- Medical, dental, and vision insurance plans with 100% premiums covered by Dyne for full-time employees and their enrolled dependents
- Short-& Long-Term Disability as well as Life Insurance with 100% of premiums covered by Dyne
- Health Reimbursement Accounts (HRA) covering 100% of the medical deductible expenses for full-time employees and their dependents enrolled in medical insurance through Dyne
- Flexible Spending Accounts
- Dependent Care Spending Accounts
- Employee Assistance Plan (EAP)
- 401(k) plan and company match
- Equity (Options and Restricted Stock Units)
- On-Site Gym
- Paid holidays and flexible paid time off, including one-week summer and one-week year-end office closures
- Paid family and parental leave
- Lunch delivered onsite daily with stipend
- Cellphone usage reimbursement, Shuttle commuter benefits & free on-site parking
Delivering for patients & community
Our mission and core values are centered on our goal to deliver functional improvement for people living with neuromuscular diseases. We have a broad pipeline including clinical programs for Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1) as well as preclinical programs for facioscapulohumeral muscular dystrophy (FSHD), Pompe disease and multiple DMD mutations. Each of these neuromuscular diseases has a profound impact on affected communities around the world.
We are utilizing our FORCE™ platform to overcome limitations in delivery to muscle and the CNS to address the root cause of neuromuscular diseases. We believe our FORCE platform provides several potential advantages, including delivery to muscle and CNS, extended time between doses and ability to re-dose.
In December 2025, we announced positive topline results from the Registrational Expansion Cohort (REC) of our DELIVER trial evaluating zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in individuals with Duchenne muscular dystrophy (DMD) amenable to exon 51 skipping. Z-rostudirsen met its primary endpoint, demonstrating a statistically significant increase in muscle content adjusted dystrophin to 5.46% of normal at six months (p<0.0001). The trial also showed improvement relative to placebo across all six prespecified functional endpoints from the topline readout of the REC, along with new long term data showing sustained functional improvement through 24 months and a continued favorable safety profile. The placebo-controlled portion of the registrational expansion cohort (REC) to support a potential regulatory submission for U.S. Accelerated Approval has been completed.
In October 2025, we announced additional one year data from our ACHIEVE clinical trial of zeleciment basivarsen (z-basivarsen, formerly known as DYNE-101), in patients with myotonic dystrophy type 1 (DM1) demonstrating clinically meaningful improvements in function and strength at the selected registrational dose. The data showed robust improvement across a diverse set of clinical measures, spanning both upper and lower limbs, along with patientreported outcomes indicating meaningful improvements in overall disease burden. These improvements were observed across measures such as hand myotonia, functional mobility tests and muscle strength assessments. The treatment also continued to exhibit a favorable safety profile.
Our trials are performed in accordance with the highest standards, including the International Conference on Harmonisation (ICH) Good Clinical Practice guidelines. Clinical trials and related protocols and patient informed consents are reviewed and approved by independent institutional review boards, ethics committees and regulatory authorities.
Dyne believes that participating in clinical trials is the best way for patients to access investigational medicines. These carefully controlled, rigorous scientific studies are needed to obtain regulatory approval, which will be critical for enabling the broadest access to treatment for a specific condition. Currently, Dyne does not have investigational medicines available through an expanded access program. We will continue to assess this as our clinical programs progress. For more information on our clinical trials, please visit here.
We are committed to listening to and learning from individuals and families living with neuromuscular diseases. They provide direct insights and information about their disease burden and what types of therapeutic benefits would make a meaningful difference in their lives, which is critical for us to develop targeted therapies designed to deliver functional improvement that really matters to patients. Our engagement includes holding patient and family advisory boards, hosting fireside chats and panel discussions with affected individuals, participating in educational webinars with the community, and engaging with advocacy organizations on disease awareness days. To hear stories from the community, please visit here.
Protecting the environment
At Dyne we recognize our responsibility to minimize the impact of our operations on the environment. At our corporate headquarters in Waltham, Massachusetts, we have implemented several practices to conserve resources and reduce waste, including those outlined below.
- We recycle paper, cardboard, plastics and glass waste. In 2025, we recycled 13.34 tons of material, which according to the U.S. Environmental Protection Agency’s (EPA) Waste Reduction Model (WARM) is the equivalent of removing annual emissions from approximately 8 passenger vehicles, 4,256 gallons of gasoline or 1,576 cylinders of propane used for home barbeques. Moreover, recycling 13.34 tons of material yields energy savings and reduces the economic impacts associated with various waste management options, equivalent to the annual energy consumption of two households, 34 barrels of oil, or an additional 1,649 gallons of gasoline.
- In 2025 we introduced composting across our Waltham office and diverted 2,124 pounds of food and organic waste from landfill, supporting our broader waste reduction goals and helping lower our greenhouse gas footprint. According to the EPA, this impact is equivalent to 14 seedlings grown for 10 years, 2,107 miles of driving offset, or 95 gallons of gasoline saved.
- We have water saver faucets, 100% LED lighting and increased energy efficiency by utilizing daylight harvesting.
- We limit the purchase of single use water bottles and distribute reusable drink containers.
- We provide onsite bike storage and showers to encourage bike commuting. We also offer onsite charging stations for employee and visitors’ electric vehicles and are members of the 128 Business Council supporting shuttle services for employees to and from public transportation hubs, helping provide innovative commuting that reduces carbon output.
In addition, we ensure our employees are trained in environmental health and safety, including emergency preparedness, proper waste disposal, and lab safety training.
Corporate governance and operating our business with integrity
Dyne’s Board of Directors has adopted Corporate Governance Guidelines to assist in the exercise of its duties and responsibilities and to serve the best interests of the company and its stockholders.
Our goal is to assemble a Board of Directors that brings to Dyne a variety of perspectives and skills derived from high quality business and professional experience. The Board has not adopted a formal policy with respect to diversity, but believes that our directors, taken as a whole, should embody a diverse set of skills, experiences and backgrounds. In this regard, the Board takes into consideration the diversity (for example, with respect to gender, race and national origin) of our Board members. The Board believes that the background and qualifications of the Board of Directors, considered as a group, should provide a significant mix of experience, knowledge and abilities that will allow the Board of Directors to fulfill its responsibilities. Our directors’ performance and qualification criteria are reviewed periodically by the Nominating and Corporate Governance Committee of the Board of Directors.
Details on our Corporate Governance Guidelines and charters for all committees are available here. The following are highlights of our corporate governance practices:
- Separate role for CEO and Chairman of the Board
- 8 of 9 Directors qualify as independent according to the applicable Nasdaq listing standards and rules and regulations of the U.S. Securities and Exchange Commission
- In 2025, each Director attended 75% or more of the aggregate number of meetings of the Board and the committees on which each director served
Directors and employees are responsible for adhering to the company’s Code of Business Conduct and Ethics. We expect our employees to read, understand and abide by the requirements in the code to ensure ethical business practices and compliance throughout our organization.
Dyne also requires that all employees adhere to anti-bribery and anti-corruption, conflicts of interest, anti-harassment, cybersecurity, and other policies and procedures that outline how they are expected to conduct their day-to-day responsibilities.
Employees and directors must report any concerns with compliance with corporate policies internally or with appropriate regulatory authorities and can do so openly or anonymously. This includes through the Dyne Therapeutics hotline at https://www.whistleblowerservices.com/DYN or utilizing a toll-free telephone number 877-306-4941.
At Dyne, we are committed to delivering meaningful functional improvement for people living with genetically driven neuromuscular diseases. As a mission‑driven organization, we pursue this goal with a shared sense of purpose and a culture grounded in transparency, respect and honesty. We hold ourselves accountable to high standards, encouraging bold thinking and learning from setbacks, knowing that our work has the potential to transform lives. We also recognize our responsibility to our stockholders, employees, the individuals and families we serve, clinicians and other stakeholders, and we remain committed to reporting our progress with clarity and integrity.
Information as of Dyne’s year-end 2025 results
